Spots Global Cancer Trial Database for Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Official Title: Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer

Study ID: NCT01860040

Conditions

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

Interventions

Cisplatin

Pemetrexed

Gemcitabine

Study Description

Brief Summary: To determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)

Detailed Description: Participants in this study will have a lung mass and are undergoing a procedure to determine if they have non-small cell lung cancer that could be removed surgically. If confirmed to have non-small cell lung cancer that can be surgically removed, he or she may be able to continue as a possible participant in this study. The purpose of this study is to determine whether neoadjuvant chemotherapy (chemotherapy that is given before surgery) will improve the amount of time a participant is free from disease in people with non-metastatic (has not spread from the original site) non-small cell lung cancer. The chemotherapy medications that will be used in this study are cisplatin and pemetrexed or cisplatin and gemcitabine and have been shown to be effective in patients with non-small cell lung cancer.